CASE #1

On Nov. 9, 2015, both Safety and Efficacy data were announced:

https://www.anavex.com/anavex-announces-positive-primary-and-secondary-endpoints-were-achieved-in-a-phase-2a-clinical-trial-of-anavex-2-73-in-alzheimers-disease%E2%80%8E/

On Nov. 3, 2015, AVXL stock price reached its peak of $14.84. This was one week ahead of the announcement.

___________________________________________________

Case #2

On Jul. 17, 2019, AVXL was invited to do an oral presentation of its Phase 2a data at AAIC